Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Pipeline Review, H2 2016

  • ID: 3960454
  • Report
  • 38 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ChemoCentryx, Inc.
  • Dompe Farmaceutici S.p.A.
  • GlaxoSmithKline Plc
  • Novartis AG
  • Syntrix Biosystems, Inc.
  • MORE
Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Pipeline Review, H2 2016

The report ‘Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Pipeline Review, H2 2016’, provides in depth analysis on Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted pipeline therapeutics.

The report provides comprehensive information on the Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
- Certain sections in the report may be removed or altered based on the availability and relevance of data.
- Updated report will be delivered in 48 hours of order confirmation.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E)
- The report reviews Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics and enlists all their major and minor projects
- The report assesses Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics

Reasons to Buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ChemoCentryx, Inc.
  • Dompe Farmaceutici S.p.A.
  • GlaxoSmithKline Plc
  • Novartis AG
  • Syntrix Biosystems, Inc.
  • MORE
Introduction

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Overview

Therapeutics Development

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Stage of Development

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Therapy Area

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Indication

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Companies

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Universities/Institutes

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Companies Involved in Therapeutics Development

eFFECTOR Therapeutics, Inc.

Ionis Pharmaceuticals, Inc.

Onconova Therapeutics, Inc.

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Drug Profiles

4EGI-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

briciclib sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISIS-EIF4ERx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBI-756 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit eIF4E for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Dormant Projects

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Discontinued Products

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Featured News & Press Releases

Nov 24, 2015: Scientists identify promising new melanoma drug

Oct 29, 2015: Onconova Therapeutics to Present New Data on Briciclib at 2015 AACR-NCI-EORTC Meeting

Apr 21, 2015: Onconova Therapeutics Highlights Briciclib at the 2015 American Association of Cancer Research (AACR) Annual Meeting

Jan 04, 2011: Isis Initiates Phase II Lung Cancer Trial With ISIS-EIF4ERx In Combination With Carboplatin And Paclitaxel

Feb 01, 2006: Lilly Initiates Clinical Trials On Second Cancer Drug Discovered In Isis Collaboration

Jun 24, 2002: Expansion Of Antisense Agreement Between Isis And Eli Lilly

List of Tables

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by eFFECTOR Therapeutics, Inc., H2 2016

Pipeline by Ionis Pharmaceuticals, Inc., H2 2016

Pipeline by Onconova Therapeutics, Inc., H2 2016

Dormant Projects, H2 2016

Discontinued Products, H2 2016

List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- ChemoCentryx, Inc.
- Dompe Farmaceutici S.p.A.
- GlaxoSmithKline Plc
- Novartis AG
- Syntrix Biosystems, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll